GlassScriptPhysician profile
Nolan Marcos
NPI 1184126831
$2,452.29
in general payments reported to CMS, 2019-2025
30 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,045 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,377.30 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $278.19 | 2024-2025 | Imfinzi |
| Janssen Biotech, INC. | $193.51 | 2024-2025 | Darzalex, Erleada, Talvey |
| Novartis Pharmaceuticals Corporation | $164.21 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $153.95 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $147.05 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Sobi, INC | $135.65 | 2024-2025 | |
| Incyte Corporation | $123.50 | 2024-2025 | Jakafi, Zynyz, Zynyz |
| Karyopharm Therapeutics INC. | $118.03 | 2024-2025 | Xpovio |
| Aveo Pharmaceuticals, INC. | $115.35 | 2024-2025 | |
| Emd Serono, INC. | $114.99 | 2024-2025 | |
| Exelixis INC. | $98.72 | 2024-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $89.37 | 2024-2025 | |
| Genmab U.S., INC. | $81.30 | 2024-2025 | Tivdak |
| Astellas Pharma US INC | $73.23 | 2024-2025 | Padcev, Vyloy |
| Stemline Therapeutics INC. | $70.97 | 2025 | Orserdu |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $66.42 | 2024-2025 | Libtayo |
| Lilly USA, LLC | $51.29 | 2024-2025 | Verzenio, Jaypirca |
| Beigene USA, INC. | $50.78 | 2025 | Brukinsa |
| Tersera Therapeutics LLC | $49.01 | 2025 | Quzyttir |
| Glaxosmithkline, LLC. | $39.35 | 2024-2025 | Ojjaara |
| Pfizer INC. | $34.98 | 2024-2025 | |
| Beone Medicines USA, INC. | $30.77 | 2025 | Brukinsa |
| Geron Corporation | $25.69 | 2024 | Rytelo |
| Agios Pharmaceuticals, INC. | $25.43 | 2025 | Pyrukynd |
| Sun Pharmaceutical Industries INC. | $24.21 | 2025 | |
| Progenics Pharmaceuticals, INC. | $22.22 | 2024 | |
| Adaptive Biotechnologies Corporation | $19.77 | 2025 | Clonoseq |
| Celgene Corporation | $18.81 | 2024 | Reblozyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.44 | 2025 | |
| Genzyme Corporation | $17.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nolan Marcos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.